🇺🇸 FDA
Pipeline program

Arm A Mylotarg plus DA Versus CPX-351

AML18

Phase 3 small_molecule active

Quick answer

Arm A Mylotarg plus DA Versus CPX-351 for Acute Myeloid Leukaemia is a Phase 3 program (small_molecule) at Cardiff Oncology with 1 ClinicalTrials.gov record(s).

Program details

Company
Cardiff Oncology
Indication
Acute Myeloid Leukaemia
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials